SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study

Annals of Oncology

Volumn 25, Issue 5, 2014, Pages 1025-1032

  Sinn, M ^a   Sinn, B V ^a   Striefler, J K ^a   Lindner, J L ^a   Stieler, J M ^a   Lohneis, P ^a   Bischoff, S ^a   Blaker H ^a   Pelzer, U ^a   Bahra, M ^b   Dietel, M ^a   Dorken B ^a   Oettle, H ^a   Riess, H ^a   Denkert, C ^a  

^a Department of Medical Oncology and Haematology ^*

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

adjuvant therapy; CONKO 001; gemcitabine; pancreatic cancer; SPARC

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; GEMCITABINE; OSTEONECTIN; SPARC PROTEIN, HUMAN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANALOGS AND DERIVATIVES; CARCINOMA, PANCREATIC DUCTAL; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, PANCREATIC DUCTAL; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEONECTIN; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84909636274     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu084     Document Type: Article

References (29)

1. Conroy, T., Desseigne, F., Ychou, M., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 (2011), 1817–1825.
2. Von Hoff, D.D., Ervin, T., Arena, F.P., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369 (2013), 1691–1703.
3. Malvezzi, M., Bertuccio, P., Levi, F., et al. European cancer mortality predictions for the year 2013. Ann Oncol 24 (2013), 792–800.
4. Oettle, H., Post, S., Neuhaus, P., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297 (2007), 267–277.
5. Sinn, M., Sinn, B.V., Striefler, J.K., et al. Long-term survival in patients with pancreatic cancer: relevant factors in CONKO-001. J Clin Oncol, 30, 2012, 4020.
6. Oettle, H., Neuhaus, P., Hochhaus, A., et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310 (2013), 1473–1481.
7. Crane, C.H., Iacobuzio-Donahue, C.A., Keys to personalized care in pancreatic oncology. J Clin Oncol 30 (2012), 4049–4050.
8. Mahadevan, D., Von Hoff, D.D., Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 6 (2007), 1186–1197.
9. Guweidhi, A., Kleeff, J., Adwan, H., et al. Osteonectin influences growth and invasion of pancreatic cancer cells. Ann Surg 242 (2005), 224–234.
10. Infante, J.R., Matsubayashi, H., Sato, N., et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 25 (2007), 319–325.
11. Von Hoff, D.D., Ramanathan, R.K., Borad, M.J., et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 29 (2011), 4548–4554.
12. Budczies, J., Klauschen, F., Sinn, B.V., et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One, 7, 2012, e51862.
13. Cox, D.R., Regression models and life-tables. J R Stat Soc Ser B (Methodol) 34 (1972), 187–220.
14. Mantoni, T.S., Schendel, R.R., Rodel, F., et al. Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma. Cancer Biol Ther 7 (2008), 1806–1815.
15. Miyoshi, K., Sato, N., Ohuchida, K., et al. SPARC mRNA expression as a prognostic marker for pancreatic adenocarcinoma patients. Anticancer Res 30 (2010), 867–871.
16. Neoptolemos, J.P., Stocken, D.D., Friess, H., et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350 (2004), 1200–1210.
17. Neoptolemos, J.P., Stocken, D.D., Bassi, C., et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304 (2010), 1073–1081.
18. Liao, W.C., Chien, K.L., Lin, Y.L., et al. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol 14 (2013), 1095–1103.
19. Bradshaw, A.D., Diverse biological functions of the SPARC family of proteins. Int J Biochem Cell Biol 44 (2012), 480–488.
20. Neuzillet, C., Tijeras-Raballand, A., Cros, J., et al. Stromal expression of SPARC in pancreatic adenocarcinoma. Cancer Metastasis Rev 32 (2013), 147–167.
21. Puolakkainen, P.A., Brekken, R.A., Muneer, S., et al. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res 2 (2004), 215–224.
22. Arnold, S.A., Rivera, L.B., Miller, A.F., et al. Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Dis Model Mech 3 (2010), 57–72.
23. Sato, N., Fukushima, N., Maehara, N., et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 22 (2003), 5021–5030.
24. Gao, J., Song, J., Huang, H., et al. Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer. J Exp Clin Cancer Res, 29, 2010, 28.
25. Gradishar, W.J., Tjulandin, S., Davidson, N., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23 (2005), 7794–7803.
26. Desai, N., Trieu, V., Yao, Z., et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12 (2006), 1317–1324.
27. Frese, K.K., Neesse, A., Cook, N., et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov 2 (2012), 260–269.
28. Desai, N., Trieu, V., Damascelli, B., et al. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol 2 (2009), 59–64.
29. Feig, C., Gopinathan, A., Neesse, A., et al. The pancreas cancer microenvironment. Clin Cancer Res 18 (2012), 4266–4276.